Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey
Authors
Keywords
-
Journal
EUROPACE
Volume 15, Issue 10, Pages 1526-1532
Publisher
Oxford University Press (OUP)
Online
2013-09-26
DOI
10.1093/europace/eut292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature
- (2013) Stefan H. Hohnloser et al. EUROPACE
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
- (2013) Hein Heidbuchel et al. EUROPACE
- Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
- (2013) Aref A. Bin Abdulhak et al. EUROPACE
- Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
- (2013) Jonathan P. Piccini et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation
- (2013) Torben Bjerregaard Larsen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention
- (2013) Morten Lamberts et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
- (2013) Willem JM Dewilde et al. LANCET
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
- (2012) Stefan H. Hohnloser et al. CIRCULATION
- Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
- (2012) Antonio L. Dans et al. CIRCULATION
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- (2012) et al. EUROPACE
- Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
- (2012) Gregory Y.H. Lip EUROPEAN HEART JOURNAL
- Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
- (2012) Leif Friberg et al. EUROPEAN HEART JOURNAL
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
- (2012) Anuraag R Kansal et al. HEART
- Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada
- (2012) Michael Sharma et al. THROMBOSIS AND HAEMOSTASIS
- Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
- (2012) Raphael Marlu et al. THROMBOSIS AND HAEMOSTASIS
- The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation
- (2012) Heyder Omran et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
- (2012) Gregory Y. H. Lip et al. THROMBOSIS AND HAEMOSTASIS
- Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor
- (2012) A. G. G. Turpie et al. THROMBOSIS AND HAEMOSTASIS
- Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter
- (2011) Laurent Gorin et al. CHEST
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
- (2011) John W. Eikelboom et al. CIRCULATION
- Dabigatran Versus Warfarin in Patients With Atrial Fibrillation
- (2011) Rangadham Nagarakanti et al. CIRCULATION
- The role of aspirin for stroke prevention in atrial fibrillation
- (2011) Gregory Y. H. Lip Nature Reviews Cardiology
- Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
- (2011) John Eikelboom et al. THROMBOSIS AND HAEMOSTASIS
- Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe
- (2011) K. Airaksinen et al. THROMBOSIS AND HAEMOSTASIS
- Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study
- (2011) Gregory Lip et al. THROMBOSIS AND HAEMOSTASIS
- Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.
- (2011) Luciano Crippa et al. THROMBOSIS AND HAEMOSTASIS
- Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
- (2011) Amitava Banerjee et al. THROMBOSIS AND HAEMOSTASIS
- Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
- (2010) Isla M. Ogilvie et al. AMERICAN JOURNAL OF MEDICINE
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
- (2009) Gregory Y.H. Lip et al. CHEST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started